A Decensi

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
    A Decensi
    Chemoprevention Unit, the Division of Epidemiology and Biostatistics, and the Division of Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 17:2633-8. 1999
  2. ncbi Chemoprevention of breast cancer: the Italian experience
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    J Cell Biochem Suppl 34:84-96. 2000
  3. ncbi Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women
    A Decensi
    FIRC Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    Eur J Cancer 35:596-600. 1999
  4. ncbi Biologic activity of tamoxifen at low doses in healthy women
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 90:1461-7. 1998
  5. ncbi Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer
    A Decensi
    Department of Medical Oncology II, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 53:145-51. 1999
  6. ncbi Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer
    A Decensi
    Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 10:1047-53. 2001
  7. pmc Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group
    A Decensi
    FIRC Chemoprovention Unit, European Institute of Oncology, Milan, Italy
    Br J Cancer 78:572-8. 1998
  8. ncbi Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women
    B Bonanni
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 69:21-7. 2001
  9. pmc Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
    M Lazzeroni
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Br J Cancer 108:1593-601. 2013
  10. ncbi Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial
    A Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 10:967-70. 2001

Collaborators

Detail Information

Publications28

  1. ncbi Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
    A Decensi
    Chemoprevention Unit, the Division of Epidemiology and Biostatistics, and the Division of Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 17:2633-8. 1999
    ..Because toxicity may be dose-dependent, we studied the biologic activity of low concentrations of tamoxifen to determine the plausibility of a dose reduction...
  2. ncbi Chemoprevention of breast cancer: the Italian experience
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    J Cell Biochem Suppl 34:84-96. 2000
    ..Moreover, updated results of the secondary prevention trial of 4-H PR and of the primary prevention trial of tamoxifen are presented. Finally, the rationale for a reduction of tamoxifen dose in future prevention trials is provided...
  3. ncbi Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women
    A Decensi
    FIRC Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    Eur J Cancer 35:596-600. 1999
    ..Our results support the observation that tamoxifen may be a suitable preventive option for women with multiple disease risk factors...
  4. ncbi Biologic activity of tamoxifen at low doses in healthy women
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 90:1461-7. 1998
    ..Since these adverse effects may be dose related, we investigated the effect of tamoxifen on several biomarkers when the drug was given at doses lower than those currently in use...
  5. ncbi Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer
    A Decensi
    Department of Medical Oncology II, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 53:145-51. 1999
    ..However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites...
  6. ncbi Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer
    A Decensi
    Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 10:1047-53. 2001
    ..Fenretinide induces a moderate decline of IGF-I levels in women < or = 50 years of age. The association between IGF-I change and the reduction of second breast cancers in premenopausal women warrants further study...
  7. pmc Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group
    A Decensi
    FIRC Chemoprovention Unit, European Institute of Oncology, Milan, Italy
    Br J Cancer 78:572-8. 1998
    ..Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity...
  8. ncbi Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women
    B Bonanni
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 69:21-7. 2001
    ..Further studies on the search of the minimal active dose of tamoxifen are warranted...
  9. pmc Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
    M Lazzeroni
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Br J Cancer 108:1593-601. 2013
    ..The post-surgical management of ductal intraepithelial neoplasia (DIN) of the breast is still a dilemma. Ki-67 labelling index (LI) has been proposed as an independent predictive and prognostic factor in early breast cancer...
  10. ncbi Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial
    A Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 10:967-70. 2001
    ..In addition, the prolonged half-life of tamoxifen and metabolite provides the rationale for a weekly administration of the drug in a preventive context. However, the clinical implications of our findings remain to be defined...
  11. pmc Tamoxifen reduces plasma homocysteine levels in healthy women
    M Cattaneo
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Ospedale Maggiore, Institute of Internal Medicine, University of Milano, Milan, Italy
    Br J Cancer 77:2264-6. 1998
    ..In conclusion, tamoxifen (20 mg day(-1) for 6 months) decreased plasma tHcy levels in healthy women. This effect may contribute to its protective effect on myocardial infarction...
  12. ncbi Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
    T Camerini
    Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 19:1664-70. 2001
    ..CONCLUSION: Given the number of patients involved in the study and the prolonged intake of the drug, the experience on fenretinide tolerability can be considered sufficiently reassuring to justify further testing of the retinoid...
  13. ncbi Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women
    B Bonanni
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Thromb Haemost 1:2149-52. 2003
    ..5-36.3) for women with low tamoxifen concentrations (< 30 ng mL-1). We conclude that tamoxifen at low doses is able to lower ultrasensitive CRP and that this might be associated with a beneficial effect on CVD...
  14. pmc Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
    R Torrisi
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br J Cancer 85:1838-41. 2001
    ..Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention...
  15. doi Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer
    A Decensi
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:582-7. 2011
    ..Studies have shown that Ki-67 response after short-term neoadjuvant aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its prognostic effect in premenopausal women is unknown...
  16. pmc The effect of metformin on apoptosis in a breast cancer presurgical trial
    M Cazzaniga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br J Cancer 109:2792-7. 2013
    ..We determined whether metformin induced a modulation of apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) overall and by insulin resistance status in a presurgical trial...
  17. doi Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study
    A Guerrieri-Gonzaga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Ann Oncol 21:949-54. 2010
    ..Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed...
  18. pmc The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial
    M Lazzeroni
    Cancer Prevention and Genetics, European Institute of Oncology, 20141 Milan, Italy
    Ecancermedicalscience 2:67. 2008
    ..Here, we investigate the changes in lipids and clotting profile in patients of the same trial...
  19. ncbi Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Cancer 36:694-709. 2000
    ..Current knowledge suggests that a pharmacological approach to preventing cancer, using natural or synthetic agents, could become an important way forward...
  20. doi Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial
    D Serrano
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Pharmacogenomics J 11:100-7. 2011
    ..Conversely, the CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. These findings support the relevance of pharmaco-genomics in tailoring tamoxifen treatment...
  21. ncbi Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
    U Veronesi
    European Institute of Oncology, Milan, Italy
    Ann Oncol 17:1065-71. 2006
    ..We conducted a long-term analysis in a subgroup of women who were regularly followed up in a single center...
  22. ncbi Chemoprevention of breast cancer with fenretinide
    R Torrisi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    Drugs 61:909-18. 2001
    ....
  23. ncbi The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives
    A Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Ann N Y Acad Sci 949:113-22. 2001
    ....
  24. ncbi Rationale for a study adding tamoxifen to HRT
    N Rotmensz
    European Institute of Oncology, Milan, Italy
    Eur J Cancer 38:S22-3. 2002
  25. pmc Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
    A Decensi
    Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy
    Br J Cancer 69:617-9. 1994
    ..Ongoing randomised trials should address this issue...
  26. ncbi Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients
    M Dowsett
    Royal Marsden NHS Trust, London, England SM2 5PT
    Cancer Epidemiol Biomarkers Prev 10:961-6. 2001
    ..This provides support for raloxifene having a breast cancer preventive effect in postmenopausal women...
  27. ncbi Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual
    G De Palo
    Istituto Nazionale Tumori, University of Milan, Italy
    Tumori 83:884-94. 1997
    ..This paper describes the rationale, design, methodology, organization, data management, statistics and accrual of the participating population...
  28. ncbi Clinical trials with retinoids for breast cancer chemoprevention
    S Zanardi
    Department of Medical and Preventive Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Endocr Relat Cancer 13:51-68. 2006
    ..The rexinoid, bexarotene, has recently been approved for the treatment of patients with cutaneous T-cell lymphoma, and a biomarker trial with bexarotene in women with high breast cancer risk is currently underway...